Xcout InteliTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with an additional office in Belgium. The company focuses on discovering and developing novel immuno-oncology therapeutics for cancer treatment.
Subscribe to see iTeos Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
iTeos Therapeutics, Inc. at a glance
iTeos Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series B2, raised $125.4M in March 2020.
iTeos Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B2 | $125.4M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
iTeos Therapeutics, Inc. competitors
A few of iTeos Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Aptevo Therapeutics Inc. is a public, clinical-stage biotechnology company headquartered in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for immuno-oncology.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company that develops novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines. Its proprietary T-win® technology is designed to modulate the tumor microenvironment by targeting both tumor cells and immune-suppressive cells, aiming to improve treatment outcomes for patients with melanoma and other tumor types.
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Get iTeos Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on iTeos Therapeutics, Inc. in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access